Researchers at Mount Sinai and Sema4 Develop Powerful New Method for Microbiome Analysis
Approach can identify antibiotic resistance and virulence markers missed by conventional techniques
Scientists from the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions New York University and the University of Florida today published a report detailing their new, more accurate method for identifying individual microbial species and strains in a community. This technique has important implications for microbiome analysis, with potential long-term applications for clinical care. The paper came out today in Nature Biotechnology.
Microbiomes are communities of bacteria, viruses, and other microbes that can be found everywhere from the surfaces of keyboards and cell phones to environments on and within us, such as our mouths or intestines. Disruption of the natural microbiome has been implicated in health conditions including infectious diseases, cancers, and complex disorders such as Crohn’s disease, ulcerative colitis, and diabetes, among many others. Successful analysis of microbiomes depends on the ability to zoom in on these communities and identify the individual species and strains living within them.
To date, most techniques for identifying microbial members of these groups provide insufficient resolution. For example, a species might only be classified as part of its broader genetic family, rather than uniquely identified on its own. Existing methods are also not effective in the characterization of an important class of genetic materials that can shuttle between different bacterial species, known as mobile genetic elements.
In this new work, scientists used Single Molecule, Real-Time Sequencing technology and novel computational tools to classify microbes for the first time by analyzing both their genetic code and their methylation patterns, a second DNA code that regulates gene activity. This more comprehensive approach using long-read sequencing proved more precise than industry-standard protocols such as 16S sequencing or short-read sequencing, correcting errors and incomplete results in microbe identification generated by those methods. Importantly, the method provides a new way to link mobile genetic elements to their bacterial hosts, allowing scientists to more accurately predict the virulence, antibiotic resistance, and other biologically and clinically critical traits of individual bacterial species and strains.
“The biomedical community has long needed a microbiome analysis method capable of resolving individual species and strains with high resolution,” said Gang Fang, PhD, Assistant Professor of Genetics and Genomic Sciences at Mount Sinai, and senior author of the paper. “We found that DNA methylation patterns can be exploited as highly informative natural barcodes to help discriminate microbial species from each other, help associate mobile genetic elements to their host-genomes and achieve more precise microbiome analysis.”
In pilot projects using both synthetic and real-world microbiome samples, scientists were able to distinguish between even closely related species and strains of bacteria. They used methylation patterns to link related DNA sequence data, providing more holistic information about individual organisms. The team validated the method in low- to medium-complexity microbial communities, and is currently developing more advanced technologies to effectively resolve high-complexity communities such as environmental microbiomes.
“This project demonstrates the sophistication and power of analyzing many types of data together to yield insights that are not possible with more simplistic approaches,” said Eric Schadt, PhD, Sema4 CEO, Dean for Precision Medicine at Mount Sinai, and a co-author of the paper. “Biology is complex, and our analyses must accurately represent that complexity if we hope to eventually deploy this information for clinical use.”
Paper cited: Beaulaurier J et al. Metagenomic binning and association of plasmids with bacterial host genomes using DNA methylation. Nature Biotechnology. Primary funding for the research was provided by the National Institutes of Health.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, an integrated health care system which includes seven hospitals and an expanding ambulatory network serving approximately 4 million patients per year.
The School has more than 1,800 students in MD, PhD, and Master’s programs and post-doctoral fellowships; more than 5,600 faculty members; over 2,000 residents and fellows; and 23 clinical and research institutes and 34 academic departments. It is ranked among the highest in the nation in National Institutes of Health funding per principal investigator. The School was the first medical school in the country to create a progressive admissions approach for students who seek early assurance of admission through the FlexMed program.
For more information, visit http://icahn.mssm.edu or find the Icahn School of Medicine at Mount Sinai on Facebook, Twitter, YouTube, and LinkedIn.
Sema4 is a health information company founded on the idea that more data, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. A Mount Sinai Health System venture based in Stamford, Conn., Sema4 is enabling physicians and consumers to more seamlessly engage the digital universe of health data, from genome test results and clinical records to wearable sensor metrics and more. The company currently offers advanced genome-based diagnostics for reproductive health and is building predictive models of complex disease. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 6,600 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 13 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke's and Mount Sinai West are ranked regionally.